A Phase 1 Ethnobridging TriaL of AGA2118 in Healthy Japanese, Chinese, and Caucasian ParticipantS (ATLAS)

Trial statusRecruiting

Trial phasePhase 1

Trial typeInterventional

Biological sexAll

Age18-65

SponsorAngitia Incorporated Limited

About this trial

This study will evaluate the effects of a single dose of AGA2118 in Japanese, Chinese, and Caucasian participants

Healthy males or females, aged 18 to 65 years

25-hydroxyvitamin D ≥30 ng/mL and agree to taking calcium and vitamin D supplements during the study

Meet the criteria for Japanese, Chinese, or Caucasian ethnicity

Participating or have participated in another clinical trial within the past 6 months

Any bone fracture within the past 6 months

History of myocardial infarction or stroke within the past 12 months

Malignancy within the past 5 years

30 Participants

are divided into 5 treatment groups

Angitia Incorporated Limited

Lead sponsor